| Quarterly Financials | Mar 2025 | Jun 2025 |
Revenue  | 165 | 119 |
| Expenses | 150 | 103 |
| EBITDA | 15 | 17 |
| Operating Profit % | 9 % | 14 % |
| Depreciation | 2 | 1 |
| Interest | 8 | 7 |
| Profit Before Tax | 7 | 9 |
| Tax | 1 | 2 |
| Net Profit | 6 | 7 |
| EPS in ₹ | 12.71 | 14.33 |
Fredun Pharmaceuticals
Fredun Pharmaceuticals
1,306.50
+14.75
(1.14%)
Market Cap
616.90 Cr
EPS
44.83
PE Ratio
31.25
Dividend Yield
0.05 %
Industry
Healthcare52 Week High
1,340.00
52 Week Low
635.00
PB Ratio
4.36
Debt to Equity
0.88
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Fredun Pharmaceuticals Board Approves Preferential Issue of Equity Shares and Convertible Warrants at Rs 1,250 Per Share2 days ago
Fredun Pharmaceuticals Limited's Board of Directors approved the issuance of up to 652,360 equity shares and 573,600 convertible warrants through a preferential issue at Rs 1,250 per share. The equity shares have a face value of Rs 10 each with a securities premium of Rs 1,240. The convertible warrants can be converted into equity shares within 18 months from allotment date, with 25% consideration payable at application and balance at conversion. The issue targets both promoters and non-promoters across 65 proposed allottees, including promoters Fredun Nariman Medhora and Daulat Medhora, along with various investment funds and individual investors. The company scheduled an Extra-Ordinary General Meeting for October 22, 2025, to seek shareholder approval for the preferential issue. The issuance is subject to shareholder and regulatory approvals including BSE Limited.
Fredun Pharmaceuticals Reports 52% Revenue Growth in Q1 FY26, Eyes Doubling Revenue in 3-4 YearsAug 06, 2025
Fredun Pharmaceuticals Limited reported strong quarterly results with revenue growing 52% year-on-year to INR 119.86 crores. EBITDA increased 62% to INR 16.99 crores with margin expansion to 14.18%, while net profit rose 64% to INR 6.77 crores. The company maintains an order book of over INR 200 crores and has 1,290 product registrations in pipeline. Management targets doubling revenue to INR 800+ crores and PAT to INR 90+ crores within 3-4 years. The diversified pharmaceutical company operates across branded generics, nutraceuticals, cosmeceuticals, animal healthcare, and mobility aids in India and 52 international markets. Fredun acquired One Pet Stop grooming platform and launched India's first 24x7 pet diagnostic center. The company aims for new age business segments including pet care, nutrition, and wellness to contribute over 51% of revenue by FY32. Current business split shows vintage business at around INR 350 crores with new age business contributing approximately INR 100-110 crores in FY25.
Fredun Pharmaceuticals Limited reported strong quarterly results with net profit rising 64% year-over-year to ₹6.77 crore in Q1 FY26, compared to ₹4.13 crore in the same period last year. Total income increased 52% to ₹119.86 crore, while EBITDA grew 62% to ₹16.99 crore. The company's EBITDA margin improved to 14.18% from 13.30%, and diluted earnings per share rose 63% to ₹14.33. The pharmaceuticals manufacturer, which operates across generics, cosmeceuticals, nutraceuticals, mobility aids and animal healthcare products, has over 1,200 products under registration and maintains an order book exceeding ₹200 crore. During the quarter, the company's subsidiary acquired a controlling stake in One Pet Stop to expand its pet care business. Fredun Pharmaceuticals also received a credit rating upgrade to IVR BBB/Stable from IVR BBB-/Stable for facilities totaling ₹139.64 crore.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,80,702.50 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,51,038.30 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,107.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,20,520.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,04,580.10 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,02,476.40 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 98,107.80 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 87,676.40 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 64,959.70 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
1,090.00 | 63,307.40 | 18.84 | 32,345.60 | 9.43 | 3,484 | -10.24 | 53.78 |
Forecast
Actual
Growth Rate
Revenue Growth
26.26 %
Net Income Growth
44.44 %
Cash Flow Change
96.95 %
ROE
14.72 %
ROCE
9.48 %
EBITDA Margin (Avg.)
4.01 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 |
| Fixed Assets | 8 | 15 | 16 | 16 | 31 | 31 | 30 | 32 | 39 | 47 | 53 |
| Current Assets | 13 | 28 | 35 | 52 | 73 | 109 | 130 | 153 | 216 | 257 | 428 |
| Capital Work in Progress | 1 | 0 | 4 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 240 |
| Other Assets | 14 | 29 | 36 | 52 | 74 | 110 | 131 | 155 | 218 | 260 | 0 |
| Total Liabilities | 23 | 43 | 56 | 79 | 105 | 141 | 162 | 187 | 257 | 308 | 487 |
| Current Liabilities | 16 | 32 | 41 | 43 | 53 | 86 | 87 | 74 | 140 | 167 | 327 |
| Non Current Liabilities | 4 | 7 | 8 | 14 | 13 | 14 | 32 | 45 | 21 | 19 | 18 |
| Total Equity | 3 | 4 | 7 | 22 | 39 | 41 | 43 | 68 | 96 | 122 | 141 |
| Reserve & Surplus | 1 | 1 | 2 | 19 | 35 | 37 | 39 | 63 | 84 | 115 | 137 |
| Share Capital | 3 | 3 | 5 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 0 | 1 | -1 | 1 | 0 | 2 | -2 | 1 | 1 | -2 |
| Investing Activities | -3 | -6 | -7 | -8 | -5 | -2 | -1 | -4 | -9 | -8 |
| Operating Activities | 2 | 3 | 4 | 17 | 1 | -11 | 0 | -2 | -14 | -0 |
| Financing Activities | 1 | 4 | 3 | -8 | 4 | 14 | -1 | 8 | 25 | 6 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Nov 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | May 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Apr 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 52.04 % | 52.04 % | 52.04 % | 51.27 % | 51.27 % | 51.27 % | 51.04 % | 51.04 % | 50.34 % | 50.15 % | 49.62 % | 49.62 % | 49.33 % | 49.31 % | 49.16 % | 49.17 % | 48.92 % | 49.17 % | 48.93 % | 48.93 % | 48.93 % | 48.93 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 1.88 % | 1.88 % | 1.88 % | 1.69 % | 1.69 % | 1.69 % | 1.68 % | 1.68 % | 1.66 % | 1.65 % | 1.64 % | 1.64 % | 1.61 % | 1.60 % | 1.60 % | 1.60 % | 1.59 % | 1.60 % | 1.59 % | 1.59 % | 1.59 % | 1.59 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 41.01 % | 40.99 % | 40.77 % | 41.56 % | 41.90 % | 41.81 % | 42.02 % | 42.08 % | 42.48 % | 43.07 % | 43.64 % | 43.60 % | 43.48 % | 43.49 % | 43.67 % | 44.02 % | 43.94 % | 43.89 % | 44.21 % | 44.55 % | 44.50 % | 44.52 % |
| Others | 5.07 % | 5.09 % | 5.32 % | 5.47 % | 5.13 % | 5.23 % | 5.25 % | 5.19 % | 5.52 % | 5.13 % | 5.10 % | 5.14 % | 5.58 % | 5.60 % | 5.58 % | 5.22 % | 5.55 % | 5.35 % | 5.27 % | 4.93 % | 4.98 % | 4.96 % |
| No of Share Holders | 0 | 1,993 | 2,301 | 3,681 | 3,674 | 3,573 | 3,620 | 3,678 | 3,901 | 4,521 | 4,609 | 4,625 | 4,627 | 4,635 | 6,315 | 7,507 | 6,840 | 7,511 | 8,018 | 8,121 | 7,976 | 7,906 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.6 | 1 | 0.65 | 0.66 | 0.7 | 0.7 | 0.7 | 0.7 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.42 | 0.24 | 0.56 | 0.14 | 0.08 | 0.09 | 0.1 | 0.1 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Sept 2025 |  Annual General Meeting | NA | 30 Sept 2025 | 1,211.90 | 1,306.50 |
| 18 Sept 2021 |  Dividend | ₹ 0.70 /share | 16 Sept 2021 | 415.70 | 454.45 |
| 22 Sept 2023 | Dividend | ₹ 0.70 /share | 22 Sept 2023 | 886.50 | 875.65 |
| 18 Jan 2024 |  Extraordinary General Meeting | NA | 18 Jan 2024 | 872.05 | 837.70 |
| 23 Sept 2024 | Dividend | ₹ 0.70 /share | 23 Sept 2024 | 981.65 | 767.60 |
| 30 Sept 2024 | Annual General Meeting | NA | 30 Sept 2024 | 788.20 | 755.65 |
| 26 Oct 2024 |  Quarterly Result Announcement | NA | 26 Oct 2024 | 774.70 | 726.85 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 700.70 | 721.85 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 724.55 | 771.00 |
| 30 Jul 2025 | Quarterly Result Announcement | NA | 30 Jul 2025 | 860.20 | 958.60 |
| 23 Sept 2025 | Dividend | ₹ 0.70 /share | 23 Sept 2025 | 771.65 | 1,216.75 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 day ago
1 day agoClosure of Trading Window1 day ago
1 day agoBoard Meeting Outcome for Outcome Of Board Meeting Held On 25Th September 2025 Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)2 days ago
2 days agoClosure of Trading Window5 days ago
5 days agoBoard Meeting Intimation for Prior Intimation Under Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (The SEBI LODR
Regulations)6 days ago
6 days agoAnnouncement under Regulation 30 (LODR)-Newspaper PublicationSep 09, 2025
Sep 09, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("SEBI Listing Regulations").Sep 08, 2025
Sep 08, 2025Intimation Of Record Date For The Purpose Of Final Dividend For The Financial Year 2024-25Sep 08, 2025
Sep 08, 2025Notice Of Book Closure For The Purpose Of 38Th Annual General Meeting (AGM)Sep 08, 2025
Sep 08, 2025Submission Of The 38Th Annual Report Of Fredun Pharmaceuticals Limited For The Financial Year 2024-25.Sep 08, 2025
Sep 08, 2025Reg. 34 (1) Annual Report.Sep 08, 2025
Sep 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Meeting UpdatesSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 23, 2025
Aug 23, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Aug 06, 2025Audio Recording Of The Q1 FY26 Earnings Conference CallAug 01, 2025
Aug 01, 2025Audio Recording Of The Q1 FY25 Earnings Conference CallAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Jul 31, 2025Appointment Of Non-Executive Independent Directors.Jul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 30, 2025
Jul 30, 2025Results For The Quarter Ended 30Th June 2025.Jul 30, 2025
Jul 30, 2025Board Meeting Outcome for Outcome Of Board MeetingJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 29, 2025
Jul 29, 2025Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Wednesday 30 July 2025.Jul 14, 2025
Jul 14, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 10, 2025
Jul 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 09, 2025
Jul 09, 2025Voluntary Disclosure - SEBI Adjudication Order Dated June 30 2025 (No Penalty Imposed)Jul 03, 2025
Jul 03, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-DemiseJun 20, 2025
Jun 20, 2025Investors Presentation Issued By Fredun Pharmaceuticals Limited Stating Annual Review & Strategic Outlook For Growth In The Pharma IndustryJun 10, 2025
Jun 10, 2025Investor Presentation Of Fredun Pharmaceuticals LimitedJun 10, 2025
Jun 10, 2025Revised Outcome Of The Board Meeting Dated 30.05.2025May 31, 2025
May 31, 2025Standalone And Consolidated Audited Financial Results For The Quarter And Financial Year Ended March 31 2025 Along With Statement Of Assets And Liabilities And Cash Flow StatementMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 31, 2025
May 31, 2025Standalone And Consolidated Financial Results For The Period Ended On 31St March 2025.May 31, 2025
May 31, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 31, 2025
May 31, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Board Meeting Intimation for Prior Intimation For The Board Meeting Of The Company To Be Held On Friday 30Th May 2025.May 22, 2025
May 22, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 17, 2025
May 17, 2025Appointment of Company Secretary and Compliance OfficerMay 17, 2025
May 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 15, 2025
Apr 15, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Apr 03, 2025
Apr 03, 2025Closure of Trading WindowMar 27, 2025
Mar 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2025
Mar 18, 2025Technical Indicators
RSI(14)
Neutral 66.12
ATR(14)
Volatile 67.78
STOCH(9,6)
Neutral 56.14
STOCH RSI(14)
Neutral 57.28
MACD(12,26)
Bearish -3.69
ADX(14)
Strong Trend 37.54
UO(9)
Bearish 52.64
ROC(12)
Uptrend And Accelerating 4.38
WillR(14)
Neutral -26.46
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
